Market Chatter: AstraZeneca Trims US Staff by 600 as Part of Cost-Cutting Program

MT Newswires Live11-14 01:13

AstraZeneca (AZN) has eliminated around 600 positions in its respiratory and immunology commercial teams in the US as part of its three-year program to cut costs and reallocate resources to developing new drugs, Bloomberg reported Friday, citing sources familiar with the matter.

At least some of the employees laid off were part of the team marketing asthma drugs Breztri and Airsupra, according to the report.

Some of the impacted staff are expected to be reassigned within the company, the report said.

AstraZeneca did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 184.57, Change: +0.19, Percent Change: +0.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment